Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 204

1.

Healthcare Costs of Patients With Biopsy-Confirmed Nonalcoholic Fatty Liver Disease are Nearly Twice Those of Matched Controls.

Hagström H, Nasr P, Ekstedt M, Hammar U, Widman L, Stål P, Hultcrantz R, Kechagias S, Henriksson M.

Clin Gastroenterol Hepatol. 2019 Oct 18. pii: S1542-3565(19)31167-X. doi: 10.1016/j.cgh.2019.10.023. [Epub ahead of print]

PMID:
31634581
2.

Alcohol and drug use prior to liver transplantation: more common than expected in patients with non-alcoholic liver disease.

Schult A, Stokkeland K, Ericzon BG, Hultcrantz R, Franck J, Stål P, Castedal M.

Scand J Gastroenterol. 2019 Sep;54(9):1146-1154. doi: 10.1080/00365521.2019.1656772. Epub 2019 Aug 27.

PMID:
31453745
3.

A nationwide cohort study of the incidence of microscopic colitis in Sweden.

Bergman D, Clements MS, Khalili H, Agréus L, Hultcrantz R, Ludvigsson JF.

Aliment Pharmacol Ther. 2019 Jun;49(11):1395-1400. doi: 10.1111/apt.15246. Epub 2019 Apr 15.

PMID:
30983010
4.

Fecal immunochemical test in cancer screening - colonoscopy outcome in FIT positives and negatives.

Ribbing Wilén H, Blom J, Höijer J, Andersson G, Löwbeer C, Hultcrantz R.

Scand J Gastroenterol. 2019 Mar;54(3):303-310. doi: 10.1080/00365521.2019.1585569. Epub 2019 Mar 23.

PMID:
30907196
5.

Rational targeting of population groups and residential areas for colorectal cancer screening.

Strömberg U, Peterson S, Holmén A, Holmberg E, Hultcrantz R, Martling A, Nilbert M.

Cancer Epidemiol. 2019 Jun;60:23-30. doi: 10.1016/j.canep.2019.01.009. Epub 2019 Mar 18.

PMID:
30897387
6.

Perforations and bleeding in a population-based cohort of all registered colonoscopies in Sweden from 2001 to 2013.

Thulin T, Hammar U, Ekbom A, Hultcrantz R, Forsberg AM.

United European Gastroenterol J. 2019 Feb;7(1):130-137. doi: 10.1177/2050640618809782. Epub 2018 Oct 23.

7.

Are anxiety levels associated with the decision to participate in a Swedish colorectal cancer screening programme? A nationwide cross-sectional study.

Wangmar J, von Vogelsang AC, Hultcrantz R, Fritzell K, Wengström Y, Jervaeus A.

BMJ Open. 2018 Dec 22;8(12):e025109. doi: 10.1136/bmjopen-2018-025109.

8.

Rates and characteristics of postcolonoscopy colorectal cancer in the Swedish IBD population: what are the differences from a non-IBD population?

Stjärngrim J, Ekbom A, Hammar U, Hultcrantz R, Forsberg AM.

Gut. 2019 Sep;68(9):1588-1596. doi: 10.1136/gutjnl-2018-316651. Epub 2018 Dec 15.

PMID:
30554159
9.

Accuracy of Noninvasive Scoring Systems in Assessing Risk of Death and Liver-Related Endpoints in Patients With Nonalcoholic Fatty Liver Disease.

Hagström H, Nasr P, Ekstedt M, Stål P, Hultcrantz R, Kechagias S.

Clin Gastroenterol Hepatol. 2019 May;17(6):1148-1156.e4. doi: 10.1016/j.cgh.2018.11.030. Epub 2018 Nov 22.

PMID:
30471458
10.

Cardiovascular risk factors in non-alcoholic fatty liver disease.

Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Askling J, Hultcrantz R, Kechagias S.

Liver Int. 2019 Jan;39(1):197-204. doi: 10.1111/liv.13973. Epub 2018 Oct 17.

PMID:
30253056
11.

A widely used sampling device in colorectal cancer screening programmes allows for large-scale microbiome studies.

Gudra D, Shoaie S, Fridmanis D, Klovins J, Wefer H, Silamikelis I, Peculis R, Kalnina I, Elbere I, Radovica-Spalvina I, Hultcrantz R, Šķenders Ģ, Leja M, Engstrand L.

Gut. 2019 Sep;68(9):1723-1725. doi: 10.1136/gutjnl-2018-316225. Epub 2018 Sep 21. No abstract available.

12.

Steatohepatitis Is Not Associated with an Increased Risk for Fibrosis Progression in Nonalcoholic Fatty Liver Disease.

Hagström H, Elfwén O, Hultcrantz R, Stål P.

Gastroenterol Res Pract. 2018 Jul 2;2018:1942648. doi: 10.1155/2018/1942648. eCollection 2018.

13.

Fecal immunochemical test in colorectal cancer screening: Colonoscopy findings by different cut-off levels.

Ribbing Wilén H, Blom J, Höijer J, Hultcrantz R.

J Gastroenterol Hepatol. 2019 Jan;34(1):103-112. doi: 10.1111/jgh.14373. Epub 2018 Jul 29.

PMID:
29968937
14.

Hepcidin levels correlate to liver iron content, but not steatohepatitis, in non-alcoholic fatty liver disease.

Marmur J, Beshara S, Eggertsen G, Onelöv L, Albiin N, Danielsson O, Hultcrantz R, Stål P.

BMC Gastroenterol. 2018 Jun 5;18(1):78. doi: 10.1186/s12876-018-0804-0.

15.

Therapeutic recommendations in HFE hemochromatosis for p.Cys282Tyr (C282Y/C282Y) homozygous genotype.

Adams P, Altes A, Brissot P, Butzeck B, Cabantchik I, Cançado R, Distante S, Evans P, Evans R, Ganz T, Girelli D, Hultcrantz R, McLaren G, Marris B, Milman N, Nemeth E, Nielsen P, Pineau B, Piperno A, Porto G, Prince D, Ryan J, Sanchez M, Santos P, Swinkels D, Teixeira E, Toska K, Vanclooster A, White D; Contributors and Hemochromatosis International Taskforce.

Hepatol Int. 2018 Mar;12(2):83-86. doi: 10.1007/s12072-018-9855-0. Epub 2018 Mar 27.

16.

Risk for development of severe liver disease in lean patients with nonalcoholic fatty liver disease: A long-term follow-up study.

Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S.

Hepatol Commun. 2017 Nov 30;2(1):48-57. doi: 10.1002/hep4.1124. eCollection 2018 Jan.

17.

Health literacy levels and views about being invited to a colorectal cancer screening program.

Wangmar J, Jervaeus A, Fritzell K, Wångdahl J, Hultcrantz R, Wengström Y.

Acta Oncol. 2018 Jun;57(6):743-749. doi: 10.1080/0284186X.2017.1420911. Epub 2018 Jan 8.

PMID:
29308944
18.

IGFBP-1 and IGF-I as markers for advanced fibrosis in NAFLD - a pilot study.

Hagström H, Stål P, Hultcrantz R, Brismar K, Ansurudeen I.

Scand J Gastroenterol. 2017 Dec;52(12):1427-1434. doi: 10.1080/00365521.2017.1379556. Epub 2017 Sep 19.

PMID:
28927302
19.

Fibrosis stage but not NASH predicts mortality and time to development of severe liver disease in biopsy-proven NAFLD.

Hagström H, Nasr P, Ekstedt M, Hammar U, Stål P, Hultcrantz R, Kechagias S.

J Hepatol. 2017 Dec;67(6):1265-1273. doi: 10.1016/j.jhep.2017.07.027. Epub 2017 Aug 10.

PMID:
28803953
20.

Translation and cultural adaption of the decisions module for colorectal cancer screening into a Swedish version - the SCREESCO questionnaire.

Fritzell K, Jervaeus A, Stake Nilsson K, Hultcrantz R, Wengström Y.

Scand J Gastroenterol. 2017 Nov;52(11):1248-1252. doi: 10.1080/00365521.2017.1357751. Epub 2017 Jul 25.

PMID:
28743223
21.

A register-based study: adverse events in colonoscopies performed in Sweden 2001-2013.

Forsberg A, Hammar U, Ekbom A, Hultcrantz R.

Scand J Gastroenterol. 2017 Sep;52(9):1042-1047. doi: 10.1080/00365521.2017.1334812. Epub 2017 May 31.

PMID:
28562115
22.

Cost-effectiveness of high-sensitivity faecal immunochemical test and colonoscopy screening for colorectal cancer.

Aronsson M, Carlsson P, Levin LÅ, Hager J, Hultcrantz R.

Br J Surg. 2017 Jul;104(8):1078-1086. doi: 10.1002/bjs.10536. Epub 2017 May 31.

23.

Pregnancy outcome in more than 5000 births to women with viral hepatitis: a population-based cohort study in Sweden.

Stokkeland K, Ludvigsson JF, Hultcrantz R, Ekbom A, Höijer J, Bottai M, Stephansson O.

Eur J Epidemiol. 2017 Jul;32(7):617-625. doi: 10.1007/s10654-017-0261-z. Epub 2017 May 26.

24.

Histologic Scores for Fat and Fibrosis Associate With Development of Type 2 Diabetes in Patients With Nonalcoholic Fatty Liver Disease.

Björkström K, Stål P, Hultcrantz R, Hagström H.

Clin Gastroenterol Hepatol. 2017 Sep;15(9):1461-1468. doi: 10.1016/j.cgh.2017.04.040. Epub 2017 May 4.

PMID:
28479500
25.

Post-colonoscopy colorectal cancers in Sweden: room for quality improvement.

Forsberg A, Hammar U, Ekbom A, Hultcrantz R.

Eur J Gastroenterol Hepatol. 2017 Jul;29(7):855-860. doi: 10.1097/MEG.0000000000000884.

PMID:
28410353
26.

The importance of people's values and preferences for colorectal cancer screening participation.

Fritzell K, Stake Nilsson K, Jervaeus A, Hultcrantz R, Wengström Y.

Eur J Public Health. 2017 Dec 1;27(6):1079-1084. doi: 10.1093/eurpub/ckw266.

PMID:
28160484
27.

Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis.

Dulai PS, Singh S, Patel J, Soni M, Prokop LJ, Younossi Z, Sebastiani G, Ekstedt M, Hagstrom H, Nasr P, Stal P, Wong VW, Kechagias S, Hultcrantz R, Loomba R.

Hepatology. 2017 May;65(5):1557-1565. doi: 10.1002/hep.29085. Epub 2017 Mar 31. Review.

28.

Development of Serum Marker Models to Increase Diagnostic Accuracy of Advanced Fibrosis in Nonalcoholic Fatty Liver Disease: The New LINKI Algorithm Compared with Established Algorithms.

Lykiardopoulos B, Hagström H, Fredrikson M, Ignatova S, Stål P, Hultcrantz R, Ekstedt M, Kechagias S.

PLoS One. 2016 Dec 9;11(12):e0167776. doi: 10.1371/journal.pone.0167776. eCollection 2016.

29.

Risk of cirrhosis-related complications in patients with advanced fibrosis following hepatitis C virus eradication.

van der Meer AJ, Feld JJ, Hofer H, Almasio PL, Calvaruso V, Fernández-Rodríguez CM, Aleman S, Ganne-Carrié N, D'Ambrosio R, Pol S, Trapero-Marugan M, Maan R, Moreno-Otero R, Mallet V, Hultcrantz R, Weiland O, Rutter K, Di Marco V, Alonso S, Bruno S, Colombo M, de Knegt RJ, Veldt BJ, Hansen BE, Janssen HLA.

J Hepatol. 2017 Mar;66(3):485-493. doi: 10.1016/j.jhep.2016.10.017. Epub 2016 Oct 22.

PMID:
27780714
30.

Low to moderate lifetime alcohol consumption is associated with less advanced stages of fibrosis in non-alcoholic fatty liver disease.

Hagström H, Nasr P, Ekstedt M, Kechagias S, Önnerhag K, Nilsson E, Rorsman F, Sheikhi R, Marschall HU, Hultcrantz R, Stål P.

Scand J Gastroenterol. 2017 Feb;52(2):159-165. doi: 10.1080/00365521.2016.1239759. Epub 2016 Oct 6.

31.

SAF score and mortality in NAFLD after up to 41 years of follow-up.

Hagström H, Nasr P, Ekstedt M, Kechagias S, Stål P, Bedossa P, Hultcrantz R.

Scand J Gastroenterol. 2017 Jan;52(1):87-91. doi: 10.1080/00365521.2016.1230779. Epub 2016 Sep 10.

32.

The underreporting of hepatocellular carcinoma to the cancer register and a log-linear model to estimate a more correct incidence.

Törner A, Stokkeland K, Svensson Å, Dickman PW, Hultcrantz R, Montgomery S, Duberg AS.

Hepatology. 2017 Mar;65(3):885-892. doi: 10.1002/hep.28775. Epub 2016 Sep 30.

PMID:
27533761
33.

HLA Associations Distinguish Collagenous From Lymphocytic Colitis.

Westerlind H, Bonfiglio F, Mellander MR, Hübenthal M, Brynedal B, Björk J, Törkvist L, Padyukov L, Ohlsson B, Löfberg R, Hultcrantz R, Franke A, Bresso F, D'Amato M.

Am J Gastroenterol. 2016 Aug;111(8):1211-3. doi: 10.1038/ajg.2016.215. No abstract available.

PMID:
27481432
34.

Overweight in late adolescence predicts development of severe liver disease later in life: A 39years follow-up study.

Hagström H, Stål P, Hultcrantz R, Hemmingsson T, Andreasson A.

J Hepatol. 2016 Aug;65(2):363-8. doi: 10.1016/j.jhep.2016.03.019. Epub 2016 Jun 16.

PMID:
27321729
35.

Reporting systems in gastrointestinal endoscopy: Requirements and standards facilitating quality improvement: European Society of Gastrointestinal Endoscopy position statement.

Bretthauer M, Aabakken L, Dekker E, Kaminski MF, Rösch T, Hultcrantz R, Suchanek S, Jover R, Kuipers EJ, Bisschops R, Spada C, Valori R, Domagk D, Rees C, Rutter MD; ESGE Quality Improvement Committee.

United European Gastroenterol J. 2016 Apr;4(2):172-6. doi: 10.1177/2050640616629079. Epub 2016 Feb 3. Review.

36.

Elevated serum ferritin is associated with increased mortality in non-alcoholic fatty liver disease after 16 years of follow-up.

Hagström H, Nasr P, Bottai M, Ekstedt M, Kechagias S, Hultcrantz R, Stål P.

Liver Int. 2016 Nov;36(11):1688-1695. doi: 10.1111/liv.13144. Epub 2016 Apr 28.

PMID:
27064133
37.

Complications after colonoscopy and surgery in a population-based colorectal cancer screening programme.

Saraste D, Martling A, Nilsson PJ, Blom J, Törnberg S, Hultcrantz R, Janson M.

J Med Screen. 2016 Sep;23(3):135-40. doi: 10.1177/0969141315625701. Epub 2016 Mar 2.

PMID:
26940962
38.

Requirements and standards facilitating quality improvement for reporting systems in gastrointestinal endoscopy: European Society of Gastrointestinal Endoscopy (ESGE) Position Statement.

Bretthauer M, Aabakken L, Dekker E, Kaminski MF, Rösch T, Hultcrantz R, Suchanek S, Jover R, Kuipers EJ, Bisschops R, Spada C, Valori R, Domagk D, Rees C, Rutter MD; ESGE Quality Improvement Committee.

Endoscopy. 2016 Mar;48(3):291-4. doi: 10.1055/s-0042-100186. Epub 2016 Feb 3.

39.

Microscopic colitis: a descriptive clinical cohort study of 795 patients with collagenous and lymphocytic colitis.

Mellander MR, Ekbom A, Hultcrantz R, Löfberg R, Öst Å, Björk J.

Scand J Gastroenterol. 2016;51(5):556-62. doi: 10.3109/00365521.2015.1124283. Epub 2015 Dec 18.

PMID:
26679722
40.

Dense genotyping of immune-related loci identifies HLA variants associated with increased risk of collagenous colitis.

Westerlind H, Mellander MR, Bresso F, Munch A, Bonfiglio F, Assadi G, Rafter J, Hübenthal M, Lieb W, Källberg H, Brynedal B, Padyukov L, Halfvarson J, Törkvist L, Bjork J, Andreasson A, Agreus L, Almer S, Miehlke S, Madisch A, Ohlsson B, Löfberg R, Hultcrantz R, Franke A, D'Amato M.

Gut. 2017 Mar;66(3):421-428. doi: 10.1136/gutjnl-2015-309934. Epub 2015 Nov 2.

PMID:
26525574
41.

Reply.

Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stal P, Kechagias S, Hultcrantz R.

Hepatology. 2016 Jul;64(1):310-1. doi: 10.1002/hep.28314. Epub 2015 Dec 23. No abstract available.

PMID:
26517017
42.

Adverse outcomes of pregnancy in women with non-alcoholic fatty liver disease.

Hagström H, Höijer J, Ludvigsson JF, Bottai M, Ekbom A, Hultcrantz R, Stephansson O, Stokkeland K.

Liver Int. 2016 Feb;36(2):268-74. doi: 10.1111/liv.12902. Epub 2015 Sep 9.

PMID:
26114995
43.

Increased risk of preterm birth in women with autoimmune hepatitis - a nationwide cohort study.

Stokkeland K, Ludvigsson JF, Hultcrantz R, Ekbom A, Höijer J, Bottai M, Stephansson O.

Liver Int. 2016 Jan;36(1):76-83. doi: 10.1111/liv.12901. Epub 2015 Jul 8.

PMID:
26098001
44.

Increased risk of non-alcoholic fatty liver disease after diagnosis of celiac disease.

Reilly NR, Lebwohl B, Hultcrantz R, Green PH, Ludvigsson JF.

J Hepatol. 2015 Jun;62(6):1405-11. doi: 10.1016/j.jhep.2015.01.013. Epub 2015 Jan 21.

45.

Application of hepatocellular carcinoma surveillance in a European setting. What can we learn from clinical practice?

Edenvik P, Davidsdottir L, Oksanen A, Isaksson B, Hultcrantz R, Stål P.

Liver Int. 2015 Jul;35(7):1862-71. doi: 10.1111/liv.12764. Epub 2015 Jan 20.

PMID:
25524812
46.

Hepatocellular and extrahepatic cancer in patients with autoimmune hepatitis--a long-term follow-up study in 634 Swedish patients.

Danielsson Borssén Å, Almer S, Prytz H, Wallerstedt S, Friis-Liby IL, Bergquist A, Nyhlin N, Hultcrantz R, Sangfelt P, Weiland O, Lindgren S, Verbaan H, Werner M.

Scand J Gastroenterol. 2015 Feb;50(2):217-23. doi: 10.3109/00365521.2014.983154. Epub 2014 Dec 8.

PMID:
25483724
47.

Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up.

Ekstedt M, Hagström H, Nasr P, Fredrikson M, Stål P, Kechagias S, Hultcrantz R.

Hepatology. 2015 May;61(5):1547-54. doi: 10.1002/hep.27368. Epub 2015 Mar 23.

48.

Five-year experience of organized colorectal cancer screening in a Swedish population - increased compliance with age, female gender, and subsequent screening round.

Blom J, Kilpeläinen S, Hultcrantz R, Törnberg S.

J Med Screen. 2014 Sep;21(3):144-50. doi: 10.1177/0969141314545555. Epub 2014 Jul 28.

PMID:
25070434
49.

Association of non-alcoholic fatty liver disease with chronic kidney disease: a systematic review and meta-analysis.

Musso G, Gambino R, Tabibian JH, Ekstedt M, Kechagias S, Hamaguchi M, Hultcrantz R, Hagström H, Yoon SK, Charatcharoenwitthaya P, George J, Barrera F, Hafliðadóttir S, Björnsson ES, Armstrong MJ, Hopkins LJ, Gao X, Francque S, Verrijken A, Yilmaz Y, Lindor KD, Charlton M, Haring R, Lerch MM, Rettig R, Völzke H, Ryu S, Li G, Wong LL, Machado M, Cortez-Pinto H, Yasui K, Cassader M.

PLoS Med. 2014 Jul 22;11(7):e1001680. doi: 10.1371/journal.pmed.1001680. eCollection 2014 Jul. Review.

50.

Evaluation of genome-wide loci of iron metabolism in hereditary hemochromatosis identifies PCSK7 as a host risk factor of liver cirrhosis.

Stickel F, Buch S, Zoller H, Hultcrantz R, Gallati S, Österreicher C, Finkenstedt A, Stadlmayr A, Aigner E, Sahinbegovic E, Sarrazin C, Schafmayer C, Braun F, Erhart W, Nothnagel M, Lerch MM, Mayerle J, Völzke H, Schaller A, Kratzer W, Boehm BO, Sipos B, D'Amato M, Torkvist L, Stal P, Arlt A, Franke A, Becker T, Krawczak M, Zwerina J, Berg T, Hinrichsen H, Krones E, Dejaco C, Strasser M, Datz C, Hampe J.

Hum Mol Genet. 2014 Jul 15;23(14):3883-90. doi: 10.1093/hmg/ddu076. Epub 2014 Feb 20.

Supplemental Content

Loading ...
Support Center